Clopidogrel Bisulfate Tablet Coating to Prevent Punch Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clopidogrel bisulfate tablets tend to strongly adhere to the punches and dies of tablet compression machines due to their hygroscopic nature, leading to sticking and surface irregularities that compromise final product quality.
Innovation Solution
The use of Colloidal Silicon Dioxide as an anti-adherent and coating agent to reduce the surface area exposure of Clopidogrel bisulfate particles, thereby decreasing adhesion to metal surfaces, combined with a formulation including Clopidogrel bisulfate, diluents, adhesives, glidants, and lubricants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Clopidogrel bisulfate is used as the active ingredient in tablet formulation, then the therapeutic effect is achieved, but the material strongly adheres to metal surfaces of punches and dies causing sticking and surface irregularities
Solution Approach 1:
The patent introduces Colloidal Silicon Dioxide as an intermediary substance between Clopidogrel bisulfate and the metal surfaces of punches and dies. This anti-adherent coating prevents direct contact and adhesion, allowing the hygroscopic drug material to be compressed without sticking to the metal surfaces, thereby maintaining both therapeutic efficacy and manufacturing quality
Solution Approach 2:
The patent applies a thin film coating of Colloidal Silicon Dioxide onto the surface of Clopidogrel bisulfate particles before tablet compression. This flexible protective shell isolates the drug material from direct contact with metal surfaces, preventing adhesion while allowing the tablet to be formed with smooth surfaces and proper debossing
2Ease of manufacture
If Clopidogrel bisulfate particles are compressed directly without coating, then the manufacturing process is simple, but the hygroscopic nature causes rapid film formation on punch surfaces leading to sticking
Solution Approach 1:
The patent applies Colloidal Silicon Dioxide coating to Clopidogrel bisulfate particles before the compression process. This preliminary anti-adherent treatment prevents the rapid film formation that would otherwise occur during compression, eliminating sticking issues and allowing continuous manufacturing without interruption for cleaning or retooling
3Object-affected harmful factors
If the surface area of Clopidogrel bisulfate particles is reduced by aggregation, then adhesion to metal surfaces decreases, but tablet homogeneity and dissolution may be affected
Solution Approach 1:
Rather than aggregating particles which would affect homogeneity, the patent uses Colloidal Silicon Dioxide as an intermediary coating on individual particles. This maintains particle dispersion and tablet homogeneity while the anti-adherent coating prevents adhesion to metal surfaces, achieving both goals simultaneously
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively prevents sticking during tablet manufacturing, resulting in smooth tablet surfaces and improved quality by uniformly distributing Colloidal Silicon Dioxide on Clopidogrel bisulfate particles, enhancing flowability and reducing adhesion issues.
Implementation Method 1
WO 2006/044548 provided solid premix based on containing Clopidogrel, there are at least one pharmaceutical excipient which is adsorbed on it
Data Source
AI summary
A solid formulation of clopidogrel bisulfate and its preparation method are disclosed. The formulation includes clopidogrel bisulfate as active ingredient, colloidal silicon dioxide as anti-adherent/coating and the carriers selected from diluent, binder, glidant, disintegrant and/or lubricant.